

**2008**  
Volume 83  
Special Supplement  
Journal of  
Dental Hygiene

# *Journal of Dental Hygiene*

THE AMERICAN DENTAL HYGIENISTS' ASSOCIATION

## **Diabetes Mellitus: Promoting Collaborations Among Health Care Professionals**

- Overview of Diabetes Mellitus
- Optometry and Diabetes Mellitus
- Podiatry and Diabetes Mellitus
- Oral Health and Diabetes
- Drug Therapy Management
- Implications for Dental Hygiene Practice

This supplement is sponsored by an educational grant from Colgate-Palmolive.

# Journal of Dental Hygiene

special supplement

## EXECUTIVE DIRECTOR

Ann Battrell, RDH, BS, MSDH  
annb@adha.net

## DIRECTOR OF COMMUNICATIONS

Jeff Mitchell  
jeffm@adha.net

## EDITOR EMERITUS

Mary Alice Gaston, RDH, MS

## EDITOR-IN-CHIEF

Rebecca S. Wilder, RDH, BS, MS  
rebeccaw@adha.net

## STAFF EDITOR

Eugenia Jefferson  
eugeniaj@adha.net

## LAYOUT/DESIGN

Jean Majeski  
Paul R. Palmer

## STATEMENT OF PURPOSE

The *Journal of Dental Hygiene* is the refereed, scientific publication of the American Dental Hygienists' Association. It promotes the publication of original research related to the profession, the education, and the practice of dental hygiene. The journal supports the development and dissemination of a dental hygiene body of knowledge through scientific inquiry in basic, applied, and clinical research.

## EDITORIAL REVIEW BOARD

Celeste M. Abraham, DDS, MS  
Cynthia C. Amyot, BSDH, EdD  
Joanna Asadoorian, AAS, BScD, MSc  
Caren M. Barnes, RDH, BS, MS  
Phyllis L. Beemsterboer, RDH, MS, EdD  
Stephanie Bossenberger, RDH, MS  
Linda D. Boyd, RDH, RD, LS, EdD  
Kimberly S. Bray, RDH, MS  
Lorraine Brockmann, RDH, MS  
Patricia Regener Campbell, RDH, MS  
Dan Caplan, DDS, PhD  
Marie Collins, RDH, EdD  
Barbara H. Connolly, PT, EdD, FAPTA  
Valerie J. Cooke, RDH, MS, EdD  
MaryAnn Cugini, RDH, MHP  
Susan J. Daniel, AAS, BS, MS  
Michele Darby, BSDH, MS  
Catherine Davis, RDH, PhD. FIDSA  
Susan Duley, BS, MS, EdS, EdD, LPC, CEDS  
Jacquelyn M. Dylla, DPT, PT  
Kathy Eklund, RDH, BS, MHP  
Deborah E. Fleming, RDH, MS  
Jane L. Forrest, BSDH, MS, EdD  
Jacquelyn L. Fried, RDH, BA, MS  
Mary George, RDH, BSDH, MEd  
Kathy Geurink, RDH, BS, MA  
Maria Perno Goldie, RDH, BA, MS  
Ellen Grimes, RDH, MA, MPA, EdD  
JoAnn R. Gurenlian, RDH, PhD  
Linda L. Hanlon, RDH, BS, MEd, PhD  
Kitty Harkleroad, RDH, MS  
Lisa F. Harper Mallonee, BSDH, MPH, RD/LD  
Harold A. Henson, RDH, MEd  
Laura Jansen Howerton, RDH, MS

Olga A.C. Ibsen, RDH, MS  
Heather L. Jared, RDH, BS, MS  
Wendy Kerschbaum, RDH, MA, MPH  
Salme Lavigne, RDH, BA, MSDH  
Jessica Y. Lee, DDS, MPH, PhD  
Madeleine Lloyd, MS, FNP-BC, MHNP-BC  
Deborah Lyle, RDH, BS, MS  
Deborah S. Manne, RDH, RN, MSN, OCN  
Ann L. McCann, RDH, BS, MS, PhD  
Stacy McCauley, RDH, MS  
Gayle McCombs, RDH, MS  
Tricia Moore, RDH, BSDH, MA, EdD  
Christine Nathe, RDH, MS  
Kathleen J. Newell, RDH, MA, PhD  
Johanna Odrich, RDH, MS, DrPH  
Pamela Overman, BSDH, MS, EdD  
Vickie Overman, RDH, BS, MEd  
Fotinos S. Panagakos, DMD, PhD, MEd  
M. Elaine Parker, RDH, MS, PhD  
Ceib Phillips, MPH, PhD  
Marjorie Reveal, RDH, MS, MBA  
Pamela D. Ritzline, PT, EdD  
Judith Skeleton, RDH, BS, MEd, PhD  
Ann Eshenaur Spolarich, RDH, PhD  
Sheryl L. Ernest Syme, RDH, MS  
Terri Tilliss, RDH, BS, MS, MA, PhD  
Lynn Tolle, BSDH, MS  
Margaret Walsh, RDH, MS, MA, EdD  
Donna Warren-Morris, RDH, MS, MEd  
Cheryl Westphal, RDH, MS  
Karen B. Williams, RDH, PhD  
Charlotte J. Wyche, RDH, MS  
Pamela Zarkowski, BSDH, MPH, JD

## BOOK REVIEW BOARD

Sandra Boucher-Bessent, RDH, BS  
Jacqueline R. Carpenter, RDH  
Mary Cooper, RDH, MEd  
Heidi Emmerling, RDH, PhD  
Margaret J. Fehrenbach, RDH, MS  
Cathryn L. Frere, BSDH, MEd  
Patricia A. Frese, RDH, BS, MEd  
Joan Gibson-Howell, RDH, MEd, EdD  
Anne Gwozdek, RDH, BA, MA

Cassandra Holder-Ballard, RDH, MPA  
Lynne Carol Hunt, RDH, MS  
Shannon Mitchell, RDH, MS  
Kip Rowland, RDH, MS  
Lisa K. Shaw, RDH, MS  
Margaret Six, RDH, BS, MSDH  
Ruth Fearing Tornwall, RDH, BS, MS  
Sandra Tuttle, RDH, BSDH  
Jean Tyner, RDH, BS

## SUBSCRIPTIONS

The *Journal of Dental Hygiene* is published quarterly, online-only, by the American Dental Hygienists' Association, 444 N. Michigan Avenue, Chicago, IL 60611. Copyright 2008 by the American Dental Hygienists' Association. Reproduction in whole or part without written permission is prohibited. Subscription rates for nonmembers are one year, \$45; two years, \$65; three years, \$90; prepaid.

## SUBMISSIONS

Please submit manuscripts for possible publication in the *Journal of Dental Hygiene* to communications@adha.net.

# Inside

## *Journal of Dental Hygiene*

### Supplement

- 2 From the Editor in Chief of the *Journal of Dental Hygiene*
- 3 Overview of Diabetes Mellitus
- 5 Optometry and Diabetes Mellitus
- 6 Podiatry and Diabetes Mellitus
- 7 Oral Health and Diabetes
- 8 Drug Therapy Management
- 8 Implications for Dental Hygiene Practice
- 10 Conclusion

This special online-only supplement to the *Journal of Dental Hygiene* was sponsored by an educational grant from Colgate-Palmolive. To obtain two hours of continuing education credit, complete the test at [www.adha.org/CE\\_courses/course21](http://www.adha.org/CE_courses/course21)

#### **Diabetes Mellitus: Promoting Collaborations Among Health Care Professionals**

#### **Objectives:**

Upon completion of this article, the reader will be able to:

1. Recognize the complexity of providing oral health care to medically compromised patients.
2. Distinguish between prediabetes and diabetes.
3. Recognize the signs and symptoms of diabetes mellitus.
4. Describe the risk factors for diabetes mellitus.
5. Identify the health problems that occur as a consequence of diabetes mellitus.
6. Explain the significance of the A1c study in determining glycemic control.
7. Identify treatment options for individuals with diabetes mellitus.
8. Describe the oral, eye and foot manifestations of diabetes mellitus.
9. Identify medication management issues that affect individuals with diabetes mellitus.
10. Explain to patients the relationship between glycemic control and periodontal/oral health.
11. Identify guidelines for providing oral health care for patients with diabetes mellitus when performing dental hygiene assessment and treatment.
12. Appreciate the role of the dental hygienist as part of an interdisciplinary team to help prevent, manage and control diabetes mellitus.
13. Increase interdisciplinary referrals for individuals with diabetes mellitus.

# From the Editor-in-Chief of the *Journal of Dental Hygiene*



The incidence of diabetes mellitus is increasing at an alarming rate. It is estimated that 23.6 million people in the United States have diabetes mellitus and another 57 million are estimated to have prediabetes. Every dental hygienist in clinical practice encounters patients who are either diagnosed with diabetes mellitus or are undiagnosed but are on the verge of having the disease. It is becoming increasingly important for all dental hygienists to stay abreast of the latest research about diabetes and know how to properly identify, treat and refer patients who present with this medical condition.

Several papers have been written regarding the potential bidirectional relationship of diabetes and periodontal disease.<sup>1,2</sup> Both diabetes mellitus and periodontal diseases are chronic inflammatory disorders and both affect millions of people worldwide. Evidence suggests that diabetes is a risk factor for increased gingivitis and periodontitis. Conversely, investigators have reported reduced glycemic control in patients who have diabetes and chronic periodontitis.

Collaboration between oral care and medical providers to treat patients with diabetes is an area where dental hygienists can play a key role. Health care providers from disciplines such as Pharmacy, Podiatry, Optometry, Dentistry, Cardiology, Endocrinology and others can work together to provide an interdisciplinary approach to treatment that will benefit the patient's overall health.

This supplement to the *Journal of Dental Hygiene* is unique in that it is co-authored by an interdisciplinary group of healthcare professionals. Dr. JoAnn Gurenlian is a dental hygienist who has a vast array of experience in the fields of dentistry and medicine. Dr. Ball, an optometrist serves as Vice Chair of the Pharmacy, Podiatry, Optometry, and Dental Professionals (PPOD) Work Group of the National Diabetes Education Program (NDEP). Dr. Fontaine, a Podiatrist, is in academic medicine in Texas and a member of the PPOD Work Group

of the NDEP. The authors share information about the interdisciplinary needs of patients with diabetes mellitus.

Finally, I want to extend tremendous thanks to the Colgate-Palmolive Company for their support of this supplement. Colgate-Palmolive is committed to providing high quality oral care products and current scientific information for dental professionals throughout the world.

**Rebecca S. Wilder, RDH, BS, MS**  
Editor-in-Chief, *Journal of Dental Hygiene*  
[RebeccaW@adha.net](mailto:RebeccaW@adha.net)

## References:

1. Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: An epidemiologic perspective. *Ann Periodontol.* 2001;6(1):99-112.
2. Taylor GW, Borgnakke WS. Periodontal disease: associations with diabetes, glycemic control and complications. *Oral dis.* 2008;14(3):191-203.

## *about the authors*

■ JoAnn R. Gurenlian, RDH, PhD, is the owner of Gurenlian & Associates, offering consulting and continuing education programs for health care providers. She has experience in general, periodontic, pediatric, and orthodontic practices, and works part-time in a medical practice. She is an internationally recognized speaker on the topics of oral pathology, oral medicine, diabetes, and women's health. She currently serves as the Vice President of the International Federation of Dental Hygienists, and Chair of the Pharmacy, Podiatry, Optometry, and Dental Professionals (PPOD) Work Group of the National Diabetes Education Program (NDEP).

■ W. Lee Ball, OD, FAAO, is an optometrist in Boston, Massachusetts. He is an adjunct professor of optometry at Beth Israel Deaconess Medical Center and Joslin Diabetes Center. Dr. Ball serves as the Vice Chair of the PPOD Work Group of the NDEP.

■ Javier La Fontaine, DPM, MS, is the chief of the podiatry section of the Central Texas Veterans health Care System and associate professor, Department of surgery, of Texas A&M University, College of Medicine in Temple, Texas. Dr. Fontaine is a member of the PPOD Work Group of the NDEP.

# Supplement

## Diabetes Mellitus: Promoting Collaboration among Health Care Professionals

JoAnn R. Gurenlian, RDH, PhD; W.Lee Ball, OD, FAAO; and Javier La Fontaine, DPM, MS

### Overview of Diabetes Mellitus

Diabetes mellitus (DM) is a chronic, metabolic disease that is associated with high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Recent statistics concerning this disease indicate 23.6 million people in the United States (US) have DM and another 57 million are estimated to have prediabetes. Approximately 25 percent of those with DM do not know they have the disease.<sup>1</sup> According to the Centers for Disease Control and Prevention, those with DM represent an increase of more than 3 million in almost two years. Almost 8 percent of the US population has diabetes. The cost of diabetes totals \$174 billion representing an increase of 32 percent since 2002.<sup>1</sup>

Diabetes can contribute to serious health complications and premature death. In 2006, DM was the seventh leading cause of death in the US and is considered to be underreported as a cause of death.<sup>1</sup> Systemic complications associated with DM appear in Table 1. A relative perspective on a daily basis indicates that 4,100 people are diagnosed with diabetes, 230 amputations occur in people with diabetes, 120 people will enter end stage renal disease programs, 55 people will go blind, and 810 will die.<sup>2</sup>

There are three main types of DM: type 1, type 2, and gestational diabetes. Type 1 diabetes accounts for approximately 5 to 10% of all cases of DM. Although type 1 DM can occur at any age, it typically affects children and young adults. Caucasians tend to have the highest rates of this type of DM. Type 1 diabetes represents an autoimmune disease characterized by the marked inability of the pancreas to secrete insulin caused by an immunologically mediated destruction of  $\beta$  cells.

### Abstract

Diabetes mellitus is a serious chronic disease that has reached epidemic proportions in the United States. The consequences of the disease are significant and costly. Managing this condition effectively requires the commitment of all health care providers, including oral health professionals. The purpose of this paper is to provide an overview of diabetes mellitus and specific concepts related to eye care, foot care, oral care, and medication management. Implications for dental hygiene practice and guidelines for providing oral health care working in collaboration with other health care providers are addressed.

### Glossary of Terms

**Diabetes mellitus** – chronic, metabolic disease associated with abnormal, high levels of blood glucose

**Prediabetes** – a condition in which blood glucose levels are higher than normal, but not in the diabetes range

**Ketosis** – accumulation in the blood and tissues of large quantities of ketone bodies such as beta-hydroxybutyric acid, acetoacetic acid and acetone; may result in a sweet or “fruity” odor to the breath.

**Ketoacidosis** – accumulation of ketone bodies causing acidosis; usually present in uncontrolled diabetes mellitus in which there is a substantial increase in fatty acid metabolism and impaired or absent carbohydrate metabolism resulting in the increased production of ketone bodies

**Polyuria** – excessive excretion of urine

**Polydipsia** – excessive thirst

**Nocturia** – excessive urination at night

**Diabetic retinopathy** – noninflammatory disease of the retina; manifestations in diabetes mellitus include microaneurysms and punctate exudate

**Neuropathy** – functional disturbances and pathologic changes in the peripheral nervous system; in diabetes, neuropathy may cause pain, weakness and wasting of proximal and distal muscles, peripheral sensory impairment, and loss of tendon reflexes

**Peripheral vascular disease** – any disorder affecting blood flow through the veins and arteries distal to the heart, which can eventually lead to ischemic necrosis and gangrene, varicose veins and thrombophlebitis

**Angiography** – radiography of vessels of the body

**Blood glucose meter** – a device used to either visually or digitally read the glucose concentration in a drop of blood; used to help adjust medication, particularly insulin use, during treatment of diabetes mellitus.



**Table 1. Complications of Diabetes Mellitus.**

System/Organ Involved	Complications
Cardiovascular	<ul style="list-style-type: none"> <li>• Heart disease death rates are 2-4 times higher</li> <li>• Risk for stroke is 2-4 times greater</li> <li>• 75% of adults with DM had hypertension</li> </ul>
Eye	<ul style="list-style-type: none"> <li>• Leading cause of blindness among adults aged 20-74 years</li> <li>• Diabetic retinopathy causes 12,000 to 24,000 new cases of blindness each year</li> </ul>
Kidney	<ul style="list-style-type: none"> <li>• Leading cause of kidney failure</li> <li>• Many living on chronic dialysis or with a kidney transplant</li> </ul>
Nervous	<ul style="list-style-type: none"> <li>• 60-70% have mild to severe forms of nervous system damage including impaired sensation of the feet, gastroparesis, carpal tunnel syndrome, and erectile dysfunction</li> </ul>
Feet	<ul style="list-style-type: none"> <li>• Almost 30% aged 40 years or older have impaired sensation in the feet</li> <li>• More than 60% of nontraumatic lower-limb amputations occur in people with DM</li> </ul>
Oral	<ul style="list-style-type: none"> <li>• Those with DM have twice the risk of periodontal infection</li> <li>• Periodontal disease is the sixth complication of DM</li> </ul>
Pregnancy	<ul style="list-style-type: none"> <li>• Major birth defects can occur in those with poorly controlled DM before conception and during the first trimester of pregnancy</li> <li>• Spontaneous abortions can occur in 15-50% of pregnancies</li> <li>• Poorly controlled diabetes during the 2nd and 3rd trimesters can result in excessively large babies and pose a risk to mother and child</li> <li>• Both the mother with gestational diabetes and the child are at greater risk for developing type 2 DM later in life</li> </ul>
Other	<ul style="list-style-type: none"> <li>• Uncontrolled diabetes can lead to ketoacidosis and hyperosmolar coma</li> <li>• More susceptible to other infections such as pneumonia or influenza</li> </ul>

*Source: Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.*

These cells are the only ones that make the hormone insulin used to regulate blood glucose. Individuals are insulin-dependent and produce no endogenous insulin. If insulin is withdrawn, ketosis and eventually ketoacidosis develops. Ketoacidosis can occur rapidly leading to coma and death. Therefore, individuals with type 1 diabetes must have insulin to survive, which is usually delivered by injection or a pump.<sup>1,3</sup>

Type 2 DM accounts for approximately 90 to 95% of all cases of DM. This disease tends to occur in older individuals, but there appears to be a growing trend in adolescents and young adults due to obesity, physical inactivity and weight management.<sup>4,5</sup> The racial/ethnic groups at particularly high risk for type 2 diabetes include African Americans, Hispanic/Latino Americans, American Indians and some Asian Americans, Native Hawaiians or Other Pacific Islanders. This form of DM usually begins as a form of peripheral insulin resistance associated with insulin secretory defect. Over time, the pancreas gradually loses its ability to produce insulin.<sup>1,3</sup>

Gestational diabetes is a form of glucose intolerance during pregnancy. It is more common among African Americans, Hispanic/Latino Americans, American Indians, obese women and those with a family history of diabetes. To avoid complications in the infant, the mother is treated with medication. Unfortunately, 5 to 10% of women with gestational diabetes develop type 2 DM immediately after pregnancy, and others have a 40 to 60% chance of developing DM in the next 5 to 10 years.<sup>1,6</sup>

There are three classic signs of DM. These include polyuria, polydipsia and nocturia. Other more subtle signs and symptoms of DM include unexplained weight loss early in the disease stage, general fatigue, increased infections, leg cramps, parasthesia of the fingers and toes, impotence, and blurred vision. These symptoms may be overlooked for an extended period of time contributing to the high number of cases of DM that are undiagnosed. Risk factors for type 2 DM appear in Table 2.

Diagnosing diabetes and prediabetes is based on clinical history, comprehen-

sive examination, and blood glucose assays. A positive diagnostic test should be followed by a repeated test on a different day to confirm the clinical diagnosis. Diagnostic criteria for prediabetes and diabetes appear in Table 3. Examples of blood assays that can be performed to identify DM include random plasma glucose, fasting plasma glucose, oral glucose tolerance test, and glycosylated hemoglobin, also known as HgA1c or A1c. The A1c test measures glucose control over time, usually reflecting blood glucose levels in the blood over 6 to 12 weeks prior to administration of the test. The A1c is a useful way for health care providers to determine if treatment protocols are effective, especially for those individuals who tend not to monitor their blood glucose regularly at home.<sup>5,7</sup>

Treatment of DM is multifaceted and includes oral medications and/or insulin, nutrition counseling, regular monitoring of blood glucose levels, regular exercise, targeted weight management, and in some cases, gastric bypass surgery or pancreatic transplant. Con-

**Table 2. Risk Factors for Diabetes Mellitus.**

To find out your risk for type 2 diabetes, check each item that applies to you:

- Age greater than 45 years
- Obesity
- Family history of type 2 diabetes
- Racial
- History of GDM or a history of delivering a baby > 9 lbs.
- History of impaired glucose tolerance or impaired fasting glucose
- Hypertension (>140/90)
- Dyslipidemia (HDL cholesterol <35mg/dL or triglyceride level >250mg/dL)
- History of cardiovascular disease
- Inactivity, exercises < 3x/week
- Other clinical conditions associated with insulin resistance (acanthosis nigricans)
- Polycystic Ovary Syndrome (PCOS)

*From: National Diabetes Information Clearinghouse. National Institute of Diabetes and Digestive and Kidney Diseases. Am I at risk for type 2 diabetes? Taking steps to lower your risk of getting diabetes. Available at: <http://diabetes.niddk.nih.gov/dm/pubs/riskfortype2/index.htm>. Accessed September 5, 2008.*

trolled trials have demonstrated that maintaining modest weight loss through sustained lifestyle interventions such as diet and physical activity reduces the incidence of type 2 DM in high-risk persons by 40 to 60 percent over 3 to 4 years. Blood pressure, cholesterol and other lipid control have also reduced diabetes complications. Lowering blood glucose reduced the risk of eye disease by 76 percent, kidney disease by 50 percent, and nerve disease by 60 percent.<sup>8-14</sup> Treatment must be tailored to individual needs, lifestyle, culture, and personal values. A one-size-fits-all approach by health care providers has shown to be ineffective in helping people with diabetes improve their health.<sup>3,15</sup>

Because DM has reached epidemic proportions in the U.S., it is incumbent upon all health professionals to assess individuals carefully to identify those who are at risk for this disease, to identify the disease in undiagnosed persons, and

**Table 3. Diagnostic Criteria for Prediabetes and Diabetes Mellitus.**

	Fasting Plasma Glucose Test (FPG)	2 – Hour Oral Glucose Tolerance Test (OGTT)
Normal	Below 100mg/dl	Below 140 mg/dl
Pre-diabetes	100-125 mg/dl (IFG)	140-199 mg/dl (IGT)
Diabetes	126 mg/dl or above	200 mg/dl or above

*Source: American Diabetes Association. Diabetes Care 2007; 30;(Suppl.1):S4-41.*

to assist those with DM in achieving optimum health. Individuals diagnosed with DM often struggle to adhere to recommended changes in diet, exercise programs, and medication management. Dental hygienists, dentists, optometrists, podiatrists, endocrinologists, diabetes educators and family care providers need to support them in their efforts and reinforce key concepts of diabetes care regularly to help them achieve successful health outcomes. Therefore, a collaborative approach among a variety of health care providers is recommended to support diabetes awareness, prevention, and management.

Health care providers representing the disciplines of Pharmacy, Podiatry, Optometry, and Dental Professionals (PPOD) of the National Diabetes Education Program (NDEP) have partnered to promote the concept of collaboration and referral to provide comprehensive diabetes care. This team created the document “Working Together to Manage Diabetes: A Guide for Pharmacy, Podiatry, Optometry, and Dental Professionals.”<sup>16</sup> Included with this document are a medication supplement, clinical images, and brochures that can be used for primary prevention for each discipline. These materials can be accessed online at [www.YourDiabetesInfo.org](http://www.YourDiabetesInfo.org).

Key concepts related to eye care, foot care, oral care, and medication management based on these documents follow.

### Optometry and Diabetes Mellitus

Diabetic retinopathy is a major public health concern in the United States, causing significant suffering, disability, loss of productivity and diminished quality of life. Diabetic retinopathy is

the fourth most common cause of preventable vision loss in adults.<sup>17</sup> Each day 55 Americans needlessly go blind from diabetes.<sup>2</sup> There are multiple levels of diabetic retinopathy ranging from mild, moderate or severe nonproliferative diabetic retinopathy to proliferative diabetic retinopathy. Between 40 and 45 percent of all Americans diagnosed with diabetes have some level of retinopathy, while vision-threatening retinopathy develops in nearly 8 percent.<sup>18</sup> Early detection leads to early treatment, which is important in reducing vision loss from this disease. With timely treatment and appropriate follow-up care, even people with advanced diabetic retinopathy can reduce the risk of blindness.


Diabetic retinopathy causes vision loss due to various diabetes-related changes in the eye. Damaged blood vessels from diabetic retinopathy cause fragile, abnormal blood vessels to develop. These new vessels (neovascularization) form when the normal retinal vessels no longer bring enough oxygen rich blood to the highly metabolic retina.<sup>19</sup> Fragile vessels can leak blood, blocking light from reaching the retina, causing loss of vision. Fluid from these leaking blood vessels can also collect in the macula, the area of the retina responsible for central vision and fine acuity, causing swelling and blurring vision. Severe retinal neovascularization and fibrous proliferation can contract causing the retina to detach, which if left untreated leads to permanent blindness. Figures 1 and 2 demonstrate detached retina and diabetic retinopathy.

The development of retinopathy depends more on the length of time a person has diabetes and the degree of glycemic control rather than his or her age. People with type 1 diabetes are at a higher risk for developing vision-threatening diabetic retinopathy. However, retinopathy and vision-threatening

retinopathy can also develop in people with type 2 diabetes who are not well controlled. The Diabetes Control and Complications Trial has shown that better control of blood sugar levels reduces the incidence of complications of diabetic retinopathy by 63 percent.<sup>19</sup> Good control of blood glucose levels is important in delaying the onset and progression of diabetic retinopathy, and can reduce its severity.<sup>19-21</sup> Other associated medical conditions known to worsen diabetic retinopathy, such as high blood pressure and high cholesterol, should also be controlled appropriately.<sup>19,20</sup>

Studies show that the early detection and treatment of diabetic retinopathy can prevent blindness.<sup>22-24</sup> The Early Treatment Diabetic Retinopathy Study demonstrated a statistically significant reduction in severe vision loss for those eyes with early treatment.<sup>24</sup> Diabetic retinopathy is most often treated with laser surgery, which seals leaking blood vessels or destroys abnormal ones. Laser treatment can reduce the onset and severity of vision loss and blindness due to diabetic retinopathy and macular edema. Pan retinal or scatter laser photocoagulation has been shown to reduce the risk of vision loss by 50 percent.<sup>24</sup> Another form of laser treatment, focal laser therapy, can reduce the risk of vision loss in patients with significant macular edema.<sup>25</sup> If a patient has blood in the center of the eye that will not resolve, a vitrectomy can be effective in restoring vision and reducing further vision loss.<sup>23</sup> A vitrectomy is a surgical procedure that removes blood and replaces the gel in the center of the eye with a salt solution.

Diabetic retinopathy is asymptomatic at early stages. A comprehensive dilated eye exam is recommended soon after diagnosis of diabetes with annual dilated exams thereafter to check for early signs of diabetic retinopathy. People with diabetic retinopathy may need an eye exam more often. The goal is to detect diabetic retinopathy before obvious symptoms develop. Although treatments have high success rates, they do not cure diabetic retinopathy. Vision that has already been lost can rarely be restored. Diagnosing the disease early is the best way to prevent permanent vision loss. With early and timely treatment and appropriate follow-up care, even people with advanced diabetic retinopathy can reduce the risk of blindness by 90 per-




**Figure 1. Vitreous retinal detachment**

cent.<sup>24</sup> People with diabetes must be made aware that a test for visual acuity, such as for glasses or a driver's license, will not detect sight-threatening retinopathy. Instead, people with diabetes should see an optometrist or ophthalmologist for a comprehensive dilated eye examination.

## Podiatry and Diabetes Mellitus

Complications from DM include serious foot problems that can lead to lower extremity amputations and long-term disability. Plantar ulceration has been reported as the most frequently common diabetic foot complication with 20%-25% of all hospital admissions owing to foot problems.<sup>26</sup> The average hospital stay for foot related conditions has been an average of 26 days.<sup>27</sup> Approximately 15% of people with diabetes will develop foot ulceration during their lifetime.<sup>28,29</sup> Therefore, foot complications are a financial burden for healthcare.

Numerous factors lead to diabetic foot complications. The most single important risk factor for foot complication is neuropathy. Neuropathy in combination with deformity such as hammertoes will lead to ulceration. Peripheral vascular disease adds to the equation poor wound healing, which will lead to infection and gangrene. Figure 3 provides an example of neuropathy and infection. Routine foot care and the foot examination are extremely important in preventing complications. Health care providers should look for risk factors leading to the diabetic foot



**Figure 2. Diabetic retinopathy**

problems including peripheral neuropathy. Patients should be counseled on the risk of developing neuropathy. About 80% of all patients with diabetes experience lack of sensation that is combined with repetitive stress with tissue break down and then eventually infection.<sup>30</sup> Patients with diabetic neuropathy alone are 1.7 times more likely to develop pedal ulcerations and are 12.1 times more likely to have foot deformities.<sup>31</sup> The etiology of diabetic neuropathy is not clearly understood, but one major theory has been described as angiopathy of the vasa nervosum causing ischemia of the nerve. Evidence of the metabolic disturbance has been found, including the accumulation of intraneural sorbitol and glycosilation of the nerve protein and reduction of



**Figure 3. Neuropathic ulcer secondary to neuropathy and deformity in a diabetic patient.**



axonal transport. Loss of protective sensation, combined with recurrent trauma, is the primary mechanism of foot breakdown. The neurological exam evaluates for deficiencies in sensation. Testing involves the use of a Semmes-Weinstein 5.07 (10-g) monofilament and 128-Hz tuning fork. Both instruments have been validated identifying patients at risk for ulcers.

It is also imperative to assess the vascular status of individuals with diabetes. The Framingham study showed peripheral vascular disease is 2-3 times more likely to develop in the persons with diabetes than the general population.<sup>32</sup> Peripheral vascular disease affects the femoral and iliac arterial systems in the same rates between diabetics and non-diabetics. However, persons with diabetes are more likely to have infrapopliteal vascular disease.<sup>33</sup> The gold standard for assessing vascular disease is angiography. Non-invasive arterial studies can be performed to assess the vascular status of the patient as well as the potential for healing. These include ankle-brachial index (ABI), toe-brachial index, toe pressures and photoplethysmography. The use of ABI in diabetics is complicated by calcification of vessels (MAC) or Monckeberg's sclerosis. This results in a "lead pipe" condition that may result in a falsely elevated blood pressure.

Foot ulcers can develop in any location of the foot. They are more common under the metatarsal heads, great toe, heel or other weight-bearing areas. Foot ulcers may also develop as a consequence of poor footwear fit creating undue pressures, frictions or irritants. The mechanism of injury is commonly described as moderate pressure with repetitive trauma in presence of neuropathy. Offloading is the key for healing the neuropathic ulceration. Different modalities exist to decrease pressure. Some of these are extra-depth shoes with inserts, off-the-shelf" off loading braces, custom molded orthosis, and the total contact cast.<sup>34</sup>

Poor glycemic control has been associated with the predisposition of diabetic patients to infections. The presences of high levels of glucose in the bloodstream decrease the ability of leukocyte chemotaxis, and phagocytosis. In general, blood glucose of 250 or more place the patients in a compromised situation



**Figure 4. Candidiasis.**  
Slide from "Diabetes and the Dental Professional" courtesy of Colgate-Palmolive Company

to develop an infection. Patients with an infected foot ulcer may have diminished signs of inflammatory reaction possibly due to peripheral neuropathy or ischemia. Many patients lack a fever, elevated white blood cell count, elevated sedimentation rate, and report no pain.<sup>35</sup> Once there is a diagnosis of clinical infection, then microbiology is a useful tool to determine the causative agent once a clinical diagnosis of infection is made. The treatment option will be dependent upon if the infection is mild, moderate or severe. The decision to hospitalize a patient or not is the question that most physicians must address. Assessing the severity of the infection helps to determine the need for hospitalization, the potential necessity and timing of surgery, and the likelihood of amputation. As a general rule, mild diseases can be treated with oral antibiotics in the outpatient setting, whereas moderate and severe disease will usually require intravenous antibiotic therapy and hospitalization.<sup>36</sup>

According to the American Diabetes Association, patients diagnosed with diabetes needs to have a foot exam yearly. Vascular and neurological exams are imperative to identify patients at risk. Those patients identified at risk for complications should have their feet checked between 3-6 months. Patients should be educated regarding foot health and shoe wear. Patients should be advised to inspect their feet daily, look for any area of redness, and call their physician if any abnormality is noticed.

## Oral Health and Diabetes

In addition to eye and foot changes, there are multiple oral signs and symp-



**Figure 5: Periodontal Abscess/ Type 1 Diabetes Mellitus**  
Slide from "Diabetes and the Dental Professional" courtesy of Colgate-Palmolive Company

toms associated with DM. These symptoms include xerostomia, burning mouth syndrome, abnormal wound healing, multiple carious lesions, candidal infection (Figure 4), acetone (fruity) breath, increased salivary viscosity and asymptomatic parotid gland swelling. These findings may be related to excessive loss of fluids through frequent urination, the altered response to infection, microvascular changes, and increased glucose concentrations in saliva.<sup>3,37,38</sup>

As noted in Table 1, periodontal disease is considered the sixth complication of DM.<sup>39</sup> People with diabetes are two to three times more likely than persons without diabetes to have periodontal disease.<sup>40</sup> Periodontal disease is more prevalent, progresses more rapidly, and is often more severe in those with both type 1 and type 2 diabetes.<sup>41</sup> Research suggests that there is a bidirectional relationship between diabetes and periodontal disease. People with diabetes are more susceptible to periodontal disease. Likewise, the presence of periodontal disease may make glycemic control more difficult to achieve.<sup>42-45</sup> Treatment of periodontal disease decreases periodontal inflammation. Evidence is accumulating to support periodontal treatment contributing to improvement of glycemic control.<sup>46</sup>

Signs of periodontal problems associated with DM include gingival proliferation, gingivitis, aggressive periodontitis, and periodontal abscesses (Figure 5). These periodontal changes reflect host-response abnormalities such as nonenzymatic glycation and oxidation, imbalance in lipid metabolism, altered collagen metabolism, and neutrophil dysfunction.<sup>47</sup> Bacterial invasion of the gingival stimulates the formation

of inflammatory mediators including interleukin-1, tumor necrosis factor-alpha (TNF- $\alpha$ ), prostaglandins, and cytokines. These inflammatory mediators led to production and activation of enzymes that destroy gingival connective tissue and resorb bone. In periodontal disease among persons with diabetes, it appears as though there is an impairment to produce new bone after bone loss has occurred. The cytokines that stimulate loss of tissue, most notably TNF- $\alpha$ , may be responsible for killing cells that repair damaged connective tissue or bone. Further, there may be more TNF- $\alpha$  produced, which can lead to an even more limited ability to repair periodontal tissues.<sup>48</sup>

## Drug Therapy Management

Drug therapy management is especially important for people with diabetes. These individuals may present with multiple diseases, take five or more medications daily, and have several health care providers. Comprehensive review of medications used and medical records, education of persons with diabetes to improve adherence with medication regimens, and an assessment of response to therapy helps to ensure timely interventions and continuity of care. More than 50 percent of those with chronic disorders do not take their medication properly. Particularly, over 60 percent of persons with diabetes do not adequately control their blood glucose. Further, of those treated for hypertension and dyslipidemia, 65 percent and 49 percent respectively were unable to reach target blood pressure and cholesterol levels.<sup>49</sup> To improve these circumstances, medication therapy regimens must be consistently and carefully monitored. Correct use of medication improves health and reduces health costs.<sup>50-52</sup>

Individuals with DM may be recommended to take either oral medications, insulin, or both. Individualized drug regimens should be determined to reduce side effects and drug interactions. Many persons with DM take non-prescription medications, vitamins, herbal or other nutritional supplements, or topical and skin care products without recognizing that these medicinals

may interact with their diabetes medication. One study reported that over 57 percent of people with diabetes use complementary and alternative therapies.<sup>53</sup> Therefore, pharmacists can advise these individuals on potential interactions, appropriateness of use based on complaint or need, and precautions and contraindications.

Another challenge for many persons with DM is regular use of a blood glucose meter. Self-monitoring blood glucose is an important way to assess the effectiveness of therapy, yet some individuals find it difficult to use the device itself or do not adhere to health care provider recommendations for regular use. Pharmacists can provide training on how to use a blood glucose meter, the results, actions to take, and when to seek help. In addition, pharmacists can offer information on ways to decrease costs of medications and supplies.

Oral health professionals need to be informed of medications being used by individuals with DM. The action of the medication, typical dosage, side effects, and particularly peak activity of insulin, are important considerations when planning dental and dental hygiene treatment. To assist with this understanding, the NDEP offers a "Diabetes Medications Supplement"<sup>54</sup> as a companion to "Working Together to Manage Diabetes." This document can be accessed online at [www.YourDiabetesInfor.org](http://www.YourDiabetesInfor.org).

## Implications for Dental Hygiene Practice

Given the connections between diabetes, oral health and systemic health, dentists and dental hygienists have an opportunity to reframe their practices to provide comprehensive care utilizing principles of oral medicine. Based on a recent forum concerning oral health and systemic health, a consensus statement was developed that defines opportunities for knowledge transfer from research to practice, collaborations among health care providers, and treatment considerations.<sup>55</sup> In addition to this international panel of experts that promoted collaboration among health care providers, a group of medical and dental experts convened in April 2007, to review evidence related to the association between diabetes, periodontal dis-

ease, and cardiovascular disease. Known as "The Scottsdale Project," the group's report detailed the importance of medical-dental collaboration in the co-management of persons at risk for or already diagnosed with diabetes who may have periodontal disease. The report provides recommendations for providing comprehensive oral health care while collaborating with medical health care providers.<sup>56</sup> Likewise, the PPOD work group of the NDEP promotes the concepts of collaboration to increase awareness of diabetes, primary prevention strategies, and effective treatment approaches.<sup>16</sup> These documents provide the basis of promoting oral health care that is based on current and relevant scientific evidence, and on a process of care that is focused on collaborative patient centered care.

Individuals who present with diabetes or prediabetes require particular attention during oral health care appointments that challenge the traditional paradigm of the 45 minute prophylaxis appointment and dental examination. Guidelines for providing care for persons with DM appear in Table 4. As can be seen from this table, comprehensive oral health care includes collaboration and consultations with other health care providers, preventive protocols to avoid emergency situations in the office, and treatment considerations.

Implementing an oral medicine approach to care for patients with DM requires a change in practice philosophy and procedures. Consideration needs to be given to modifying appointment time frames for these individuals. A longer initial appointment to allow for comprehensive assessment and treatment plan development is needed. A re-evaluation appointment needs to be scheduled to assess improvement in oral health and to determine whether or not further treatment is indicated. Further, a continuing care schedule needs to be individualized based on the patient's oral health and medical health. The traditional six month "recall" appointment will likely not be appropriate for many patients with diabetes and significant periodontal problems. The guidelines that appear in Table 4 address more frequent appointment scheduling until periodontal health has been achieved.

In addition, oral health providers must be prepared to promote health

**Table 4. Guidelines for Providing Oral Health Care for Patients with Diabetes Mellitus.**

**Front Office Staff Preparation**

- Prepare a telephone script to screen for diabetes and to customize first appointment
- Advise patients to bring list of medications used, physician contact information, and to arrive early to complete health history forms
- If ample time, mail forms in advance to patient
- Inform patient that initial appointments will be lengthy to allow for comprehensive examinations and education
- Offer morning appointments; schedule periodic breaks if long procedures planned

**Recognize early signs and symptoms of uncontrolled DM in an unsuspecting patient**

**Perform thorough medical history**

- Document medications taken
- Document frequency of blood glucose screenings and results
- Document frequency of hypoglycemic episodes

**Evaluate oral complaints/findings which appear due to abnormal neutrophil function. Microangiopathy, and altered oral microflora:**

- Dry, burning mouth
- Gingival proliferation, gingivitis, periodontitis
- Abnormal wound healing
- Multiple carious lesions
- Candidal infection – denture sore mouth, angular cheilitis, median rhomboid glossitis
- Periodontal abscesses
- Acetone breath
- Increased salivary viscosity
- Asymptomatic parotid gland swelling

Based on above findings in known DM but uncontrolled, or suspected DM case, medical referral is warranted as is referral for laboratory screening for diabetes

**Frequent oral prophylaxis/debridement is needed to minimize periodontal infection**

- Periodontal infections should be managed aggressively with antibiotic therapy
- Cultures recommended
- Monitor wound healing and response to therapy
- Prophylactic antibiotics recommended for poorly controlled patients with DM
- Inform patient periodontal treatment improves disease control

**Utilize stress reduction strategies**

- Patient may require additional insulin during appointment
- Short morning appointments are usually best
- If patient is taking insulin, know type, how often it is used, and when peak insulin activity occurs to avoid hypoglycemia medical emergency
- If long appointment, allow for short break or snack
- Use semi-supine position if GI side effects are problematic

**Reinforce proper nutrition, exercise, medication regimens, monitoring of blood glucose, need for regular eye exams, foot exams, oral health exams and medication management and review; refer to appropriate health care provider for additional evaluations**

**Use local anesthetics containing vasoconstrictors with caution**

- Epinephrine antagonizes the action of insulin and in large doses can cause hyperglycemia
- Make certain patient has taken daily dose of insulin prior to treatment

**Monitor vital signs and evaluate for signs of hypoglycemia and insulin shock**

- Weakness, trembling, hunger, sweating, tachycardia, confusion, anxiety
- Progresses to combativeness and incoherence
- Leads to unconsciousness, sweating, hypotension and hypothermia
- Treat with rapid administration of glucose, keep sugar source available chairside for hypoglycemia reversal
- If patient is taking alpha glucosidase inhibitors (Precose® or Glyset®), must use glucose, not sucrose or fructose

Stress meticulous plaque control and regular periodontal maintenance appointments (every 1-2 mos until well controlled); discuss relationship between DM and periodontal disease

*From: Vernillo AT: Dental considerations for the treatment of patients with diabetes mellitus. JADA. 2003; 134: 24S-33S. Levin RP: How treating your patients with diabetes can enhance your practice: recommendations for practice management. JADA. 2003; 134:49S-53S. Gurenlian JR: Diabetes mellitus: overview and guidelines for providing oral health care. Cont Oral Hyg. 2001; 1(1):14-16, 18-20. Gurenlian, JR. Diabetes mellitus: strategies for providing comprehensive care. Continuing Education for the Healthcare Professional (CEHP), distributed by Sullivan-Schein, a Henry Schein Company, course reference #05AS2904, 2005.*

**Table 5. Key Prevention Messages for Individuals with Diabetes.**

**Eye Care**

Recent changes in eyesight: blurred vision, blindness, floaters, flashlights, signs of infections (red, painful eyes)  
Remind patient to seek annual dilated eye examination yearly or immediately if above eye changes occur  
Remind patient to keep eye glasses/contact lens prescriptions current

**Foot Care**

Remind patient to inspect feet daily for signs of infection of neuropathy (foot ulcers, redness, burning, tingling, numb or cold feet)  
Remind patient to have periodic exams (every 3-4 mos) with foot care specialist and not to cut toe nails or self-treat foot problems  
Remind patients to remove their shoes every time they see a medical primary care provider

**Pharmacy**

Take all medications as prescribed  
Ask the pharmacist if any prescribed medications, vitamins, or herbal products will affect diabetes

**Oral Care**

Encourage patient to maintain daily mouth care, brushing teeth after eating to remove plaque and flossing at least once each day  
Remind patient to conduct a monthly self-examination and to contact the dental hygienist or dentist if they notice signs of infection, such as sore, swollen, or bleeding gums, or mouth ulcers  
Encourage patient to eat healthy snacks, choosing foods that are low in sugar and fat  
Remind patients to have periodic dental and periodontal examinations, every 3 months or more, as recommended by their oral health professional  
Encourage patients to achieve their best glycemic control possible; controlled diabetes improves oral health and maintaining good oral health helps to control diabetes

**Other Health Messages**

Do not smoke or chew tobacco  
Have blood pressure and cholesterol checks performed regularly  
Exercise regularly  
Reduce stress  
Eat a healthy diet  
Get vaccinated to protect against pneumonia and flu

*Adapted from: Centers for Disease Control and Prevention. Working Together to Manage Diabetes: A Guide for Pharmacists, Podiatrists, Optometrists, and Dental Professionals. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 2007.*

practices beyond traditional brushing and flossing reminders. Key preventive messages to promote a healthy lifestyle and better manage diabetes related conditions should be offered. Sample key preventive messages for patients with DM appear in Table 5. As can be seen from this table, the key concepts support regular evaluations with health care

specialists, promoting medical-dental collaboration.

When oral health care providers give preventive and control messages to patients with DM, it is important to consider that not all messages can be provided at one appointment. Messages should be prioritized and customized according to individual needs. Key mes-

sages can be provided in the form of computer generated reminder notes or prescriptives that are handwritten. Further, the clinician should document which messages were provided and the patient's response.

To establish a broader base for relaying health prevention and control messages about diabetes, the dentist and dental hygienist can offer this information through office newsletters or provide health awareness screening and education programs for patients with diabetes. In addition, the oral health providers can establish a broad referral base that includes other health care professionals such as optometrists, podiatrists, pharmacist, diabetes educators, family practitioners, and cardiologists. These individuals may not be aware of oral considerations and connections with DM. They may welcome the opportunity to collaborate and participate in continuing education programs, study clubs, and health awareness programs. Likewise, persons with diabetes may not know which health care provider to contact when experiencing a diabetes-related symptom or complication. Having a strong referral base will provide them an opportunity to seek care with informed specialists.

Further, oral health providers must develop a presence within the community to create greater awareness of the relationship between oral health and systemic health. Offering health education programs to the community, sponsoring wellness fairs, and conducting screening programs may help them view dentists and dental hygienists as partners in promoting improved total health.

**Conclusion**

Diabetes mellitus is a chronic disease that can be managed through medication and lifestyle changes. Serious systemic and oral complications can occur as a result of this disease. Because the disease has reached epidemic proportions in the U.S., it is essential that all health care providers, including oral health professionals, screen for those who are at risk for the disease, identify the disease in undiagnosed individuals, and assist those with diabetes in achieving optimum oral and total health.



## References

- Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
- National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2005.
- Little JW, Falace DA, Miller CS, Rhodus NL. Dental management of the medically compromised patient, 7th ed. 2008. St. Louis: Mosby Elsevier, 212-235.
- Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005;353:2643-2653.
- Mensing C. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2006;29(Suppl 1):S43-S48.
- Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease, 7th ed. 2005. Philadelphia: Elsevier Saunders, 1189-1207.
- Mensing C. Standards of medical care in diabetes – 2006. *Diabetes Care.* 2006;29(suppl 1):S4-S42.
- Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002;346:393-403.
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med.* 1993;329:977-86.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS) Group. *Lancet.* 1998;352:837-53.
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. UK Prospective Diabetes Study Group. *BMJ.* 1998;317:703-13.
- Goldberg RB, Mleeies MJ, Sacks FM, Moyé LA, et al. Cardiovascular events and their reduction with pravastatin and diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels; Subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. *Circulation.* 1998;98:2513-9.
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet.* 2000;355:253-9.
- Schwartz JS, Boccuzzi SJ, Glick H, Cook JR, et al. Cost-effectiveness of LDL-C reduction in diabetic CHD patients: Implications from the Scandinavian Simvastatin Survival Study (4S). *Circulation.* 1997;96(Suppl 1):1504-5 [Abstract].
- Sack K: Doctors miss cultural needs, study says. *The New York Times.* June 10, 2008. Available at <http://www.nytimes.com/2008/06/10/health/10study.html>. Accessed June 10, 2008.
- Centers for Disease Control and Prevention. Working Together to Manage Diabetes: A Guide for Pharmacists, Podiatrists, Optometrists, and Dental Professionals. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 2007.
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. "Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years After a Trial of Intensive Therapy." *N Engl J Med.* 2000;342: 381-89.
- Kempen, J.H. et al. "The Prevalence of Diabetic Retinopathy Among Adults in the United States." *Archives of Ophthalmology* 2004;122.4: 552-63.
- Ashton N: Studies of the retinal capillaries in relation to diabetic and other retinopathies. *Br J Ophthalmology.* 1963;47:521-538.
- Fong, D.S., et al. "American Diabetes Association. Retinopathy in Diabetes." *Diabetes Care.* 2004; 27 (suppl. 1): S4-87.
- Moss, S.E., R. Klein, and B.E. Klein. "The 14-year Incidence of Visual Loss in a Diabetic Population." *Ophthalmology.* 1998;105.6:998-1003.
- The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical applications of Diabetic Retinopathy Study (DRS) findings: DRS Report Number 8. *Ophthalmology.* 1981;88:583-600.
- The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: DRVS Report Number 5. *Arch Ophthalmol.* 1990;108:958-964.
- Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS Report Number 9. *Ophthalmology.* 1991;98(suppl): 767-785.
- ETDRS Research Group. Photocoagulation for diabetic macular edema. ETDRS Report Number 1. *Arch Ophthalmol.* 1985;103:1796-1806.
- Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. *Diabetes Care.* 1999;22:382-387.
- Currie CJ, Morgan CL, Peters JR: The epidemiology and cost of inpatient care for peripheral vascular disease infection, neuropathy and ulceration in diabetes. *Diabetes Care.* 1998;21:42-48.
- King H, Aubert RD, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. *Diabetes Care.* 1998; 21:1414-31.
- Laing P. The development and complications of diabetic foot ulcers. *American Journal of Surgery.* 1998;76:5S-10S.
- Jeffcoate WJ, Harding KG. Diabetic Foot Ulcers. *Lancet.* 2003;361-1545-1551.
- Armstrong DJ, Lavery LA, Harkless LB: Treatment-based classification system for assessment and care of diabetic feet. *JAPMA.* 1996;86:311-316.
- Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham Study. *J Am Med Assoc.* 1979;241: 2035-2038.
- Akbari CM, Pomposelli FB, Gibbons GW, Campbell DR, Pulling MC, Mydlarz D, LoGerfo FW: Lower extremity revascularization in diabetes. *Arch Surg.* 2000; 135:452-456.
- Armstrong DG, Nguyen HC, Lavery LA, VanSchie CHM, Boulton AJM, Harkless LB, Off-Loading the Diabetic Foot Wound: A randomized clinical trial: *Diabetes Care.* 2001;24(6):1019-1022.

35. Armstrong DG, Lavery LA, Sariaya M, Ashry H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. *JFAS*. 1996; 35:281.
36. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. 2004;39(7):885-910.
37. Vernillo AT. Diabetes mellitus: relevance to dental treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2001;91(3):263-270.
38. Southerland JH, Taylor GW, Offenbacher S. Diabetes and periodontal infection: making the connection. *Clinical Diabetes*. 2005;23(4):171-178.
39. Loe H. Periodontal disease: the sixth complication of diabetes mellitus. *Diabetes Care*. 1993;16(1):329-34.
40. Mealey BL, Oates TW. Diabetes mellitus and periodontal diseases. *J Periodontol*. 2006;77:1289-1303.
41. U.S. Department of Health and Human Services. *Oral Health in America: A Report of the Surgeon General*. Rockville, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Dental and Craniofacial Research, 2000.
42. Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: An epidemiologic perspective. *Ann Periodontol*. 2001;6(1):99-112.
43. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: Two-way relationship. *Ann Periodontol*. 1998;3(1):51-61.
44. Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, et al. Treatment of periodontal disease in diabetics reduces glycosylated hemoglobin. *J Periodontol*. 1997;68(8):713-9.
45. Taylor GW, Burt BA, Becker MP, Genco RJ, et al. Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. *J Periodontol*. 1996;67(10 Suppl):108S-93.
46. Donahue RP, Wu T. Insulin resistance and periodontal disease: An epidemiologic overview of research needs and future directions. *Ann Periodontol*. 2001;6(1):119-24.
47. Ryan ME, Carnu O, Kamer A. The influence of diabetes on the periodontal tissues. *JADA*. 2003;134:34S-40S.
48. Graves DA, Al-Mashat H, Liu R. Evidence that diabetes mellitus aggravates periodontal diseases and modified the response to an oral pathogen in animal models. *Compend Contin Ed Dent*. 2004; 25(7) (Suppl 1):38-46.
49. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA*. 2004;291(3):335-342.
50. Galt KA. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs Medical Center. *Pharmacotherapy*. 1998;8(5):1103-11.
51. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project IMPACT: Hyperlipidemia. *J Am Pharm Assoc*. 2000;40(2):157-65.
52. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). *Arch Intern Med*. 2002;162(10):1149-55.
53. Yeh G, Eisenberg D, Davis R, Phillips R. Use of complementary and alternative medicine among persons with diabetes mellitus: Results of a national survey. *Am J Pub Health*. 2002;92:1648-52.
54. Centers for Disease Control and Prevention. *Diabetes Medication Supplement: Working Together to Manage Diabetes*. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 2007.
55. Oral and systemic health: consensus statement from an international panel. *Inside Dentistry*. 2006;2(Special Issue 1):1-9.
56. Hein C, Cobb C, Iacopino A. Report of the independent panel of experts of 'The Scottsdale Project'. Published as a special supplement to *Grand Rounds in Oral-Sys Med*. 2007;3.

## CE Questions

This special online-only supplement to the *Journal of Dental Hygiene* was sponsored by an educational grant from Colgate-Palmolive. To obtain two hours of continuing education credit, complete the test at

[www.adha.org/CE\\_courses/course21](http://www.adha.org/CE_courses/course21)

1. Prediabetes is a condition in which blood glucose levels are higher than normal, but not in the diabetes range. Prediabetes represents impaired fasting glucose above 125 mg/dl or impaired glucose tolerance greater than 200 mg/dl.
  - a. Both statements are true
  - b. Both statements are false
  - c. The first statement is true, the second statement is false
  - d. The first statement is false, the second statement is true
2. What percentage of people do not know they have diabetes mellitus?
  - a. 15%
  - b. 25%
  - c. 35%
  - d. 45%
3. Classic signs of diabetes mellitus include:
  - a. increased thirst and urination
  - b. increased blood flow and edema
  - c. decreased infections and sensations
  - d. vision loss and foot ulcerations
4. Systemic complications of diabetes mellitus include:
  - a. increased thirst and urination
  - b. increased blood flow and edema
  - c. decreased infections and sensations
  - d. vision loss and foot ulcerations

5. The blood assay used to measure control of blood glucose over a period of 6 to 12 weeks is the:
  - a. random plasma glucose
  - b. fasting plasma glucose
  - c. oral glucose tolerance test
  - d. glycosulated hemoglobin
  
6. Treatment of diabetes includes insulin, oral medications and nutrition management. Controlled trials have demonstrated that maintaining modest weight loss with regular physical activity reduces the incidence of type 2 diabetes in high risk persons.
  - a. Both statements are true
  - b. Both statements are false
  - c. The first statement is true, the second statement is false
  - d. The first statement is false, the second statement is true
  
7. Diabetic retinopathy is:
  - a. asymptomatic in early stages
  - b. worsened by hypertension
  - c. can lead to retinal detachment and blindness
  - d. all of the above
  
8. Age is a significant factor in the development of diabetic retinopathy. This condition can be cured by laser surgery.
  - a. Both statements are true
  - b. Both statements are false
  - c. The first statement is true, the second statement is false
  - d. The first statement is false, the second statement is true
  
9. The most common foot complication associated with diabetes is:
  - a. lower extremity amputation
  - b. hammertoes
  - c. plantar ulceration
  - d. peripheral vascular disease
  
10. The gold standard used to assess for peripheral vascular disease is:
  - a. angiography
  - b. ankle-brachial index
  - c. toe pressures
  - d. photoplethysmography
  
11. Blood glucose at what level or more places an individual at greater risk for developing foot infection?
  - a. 150 mg/dl
  - b. 200 mg/dl
  - c. 250 mg/dl
  - d. 300 mg/dl
  
12. The sixth complication of diabetes mellitus is:
  - a. end stage renal disease
  - b. periodontal disease
  - c. vision loss or blindness
  - d. neuropathy
  
13. Research suggests that people with diabetes are more susceptible to periodontal disease. Further, the presence of periodontal disease may make glycemic control more difficult to achieve.
  - a. Both statements are true
  - b. Both statements are false
  - c. The first statement is true, the second statement is false
  - d. The first statement is false, the second statement is true
  
14. Oral signs of diabetes mellitus include all of the following EXCEPT one. Which one is the EXCEPTION?
  - a. periodontal abscesses
  - b. candidal infection
  - c. carious lesions
  - d. herpes infection
  
15. Oral health professionals need to be informed of medications used by individuals with diabetes mellitus, including which of the following:
  - a. action of the medication
  - b. dosage
  - c. peak activity
  - d. all of the above